247 related articles for article (PubMed ID: 10915092)
1. Biological considerations in the development of a human immunodeficiency virus vaccine.
Nathanson N; Mathieson BJ
J Infect Dis; 2000 Aug; 182(2):579-89. PubMed ID: 10915092
[TBL] [Abstract][Full Text] [Related]
2. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.
Hone DM; DeVico AL; Fouts TR; Onyabe DY; Agwale SM; Wambebe CO; Blattner WA; Gallo RC; Lewis GK
J Hum Virol; 2002; 5(1):17-23. PubMed ID: 12352264
[TBL] [Abstract][Full Text] [Related]
3. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
[TBL] [Abstract][Full Text] [Related]
4. Rethinking globally relevant vaccine strategies to human immunodeficiency virus type-1.
Gray CM; Puren AJ
Arch Immunol Ther Exp (Warsz); 2000; 48(4):235-41. PubMed ID: 11059639
[TBL] [Abstract][Full Text] [Related]
5. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
[TBL] [Abstract][Full Text] [Related]
6. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
[TBL] [Abstract][Full Text] [Related]
7. A review of vaccine research and development: the human immunodeficiency virus (HIV).
Girard MP; Osmanov SK; Kieny MP
Vaccine; 2006 May; 24(19):4062-81. PubMed ID: 16530298
[TBL] [Abstract][Full Text] [Related]
8. Diversity considerations in HIV-1 vaccine selection.
Gaschen B; Taylor J; Yusim K; Foley B; Gao F; Lang D; Novitsky V; Haynes B; Hahn BH; Bhattacharya T; Korber B
Science; 2002 Jun; 296(5577):2354-60. PubMed ID: 12089434
[TBL] [Abstract][Full Text] [Related]
9. AIDS vaccine development: the long and winding road.
Garber DA; Feinberg MB
AIDS Rev; 2003; 5(3):131-9. PubMed ID: 14598562
[TBL] [Abstract][Full Text] [Related]
10. Maturation of immune responses to lentivirus infection: implications for AIDS vaccine development.
Montelaro RC; Cole KS; Hammond SA
AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S255-9. PubMed ID: 9814952
[TBL] [Abstract][Full Text] [Related]
11. [AIDS vaccines: promises and reality].
Goudsmit J
Ned Tijdschr Geneeskd; 2001 Jun; 145(26):1241-5. PubMed ID: 11455689
[TBL] [Abstract][Full Text] [Related]
12. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 vaccine clinical trials: the Brazilian experience.
Ersching J; Pinto AR
Rev Med Virol; 2009 Sep; 19(5):301-11. PubMed ID: 19650156
[TBL] [Abstract][Full Text] [Related]
14. Progress and obstacles in the development of an AIDS vaccine.
Letvin NL
Nat Rev Immunol; 2006 Dec; 6(12):930-9. PubMed ID: 17124514
[TBL] [Abstract][Full Text] [Related]
15. Challenges in the development of an effective HIV vaccine: current approaches and future directions.
Klein E; Ho RJ
Clin Ther; 2000 Mar; 22(3):295-314; discussion 265. PubMed ID: 10963285
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B
Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study.
Cao H; Kaleebu P; Hom D; Flores J; Agrawal D; Jones N; Serwanga J; Okello M; Walker C; Sheppard H; El-Habib R; Klein M; Mbidde E; Mugyenyi P; Walker B; Ellner J; Mugerwa R;
J Infect Dis; 2003 Mar; 187(6):887-95. PubMed ID: 12660934
[TBL] [Abstract][Full Text] [Related]
18. The prospects for vaccines against HIV-1: more than a field of long-term nonprogression?
Sheppard N; Sattentau Q
Expert Rev Mol Med; 2005 Feb; 7(2):1-21. PubMed ID: 15710051
[TBL] [Abstract][Full Text] [Related]
19. [HIV/AIDS vaccines: heading for new vaccine approaches?].
Girard MP
Bull Soc Pathol Exot; 2008 Jun; 101(3):220-6. PubMed ID: 18681215
[TBL] [Abstract][Full Text] [Related]
20. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
